THOR MEDICAL ASA financials
THOR MEDICAL ASA
5967007LIEEXZXG6DK30 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Employee benefits expense | NOK 14.9M | NOK 3.3M |
| Depreciation & amortisation | NOK 2.4M | NOK 331.0K |
| Operating profit (EBIT) | -NOK 43.9M | -NOK 7.2M |
| Net finance income / (cost) | NOK 1.3M | NOK 1.6M |
| Profit before tax | -NOK 42.6M | -NOK 26.6M |
| Income tax expense | -NOK 430.0K | NOK 0 |
| Profit for the year | -NOK 42.2M | -NOK 26.6M |
| — attributable to owners | -NOK 42.2M | -NOK 29.1M |
| Total comprehensive income | -NOK 42.2M | -NOK 29.1M |
| Per share | ||
| Basic EPS | NOK -0.18 | NOK -0.15 |
| Diluted EPS | NOK -0.18 | NOK -0.15 |
| Free cash flow / share | NOK -0.10 | NOK -0.36 |
| Cash flow statement | ||
| Net cash from operating activities | -NOK 24.0M | -NOK 64.1M |
| Net cash from investing activities | NOK 1.6M | NOK 6.3M |
| Purchase of PP&E (capex) | NOK 140.0K | NOK 0 |
| Net cash from financing activities | NOK 104.0M | -NOK 332.0K |
| Lease liability payments | NOK 483.0K | NOK 159.0K |
| Balance sheet | ||
| Total assets | NOK 414.4M | NOK 330.8M |
| Non-current assets | NOK 284.5M | NOK 285.5M |
| Property, plant & equipment | NOK 615.0K | NOK 1.0M |
| Right-of-use assets | NOK 813.0K | NOK 0 |
| Intangible assets & goodwill | NOK 283.0M | NOK 284.5M |
| Current assets | NOK 129.9M | NOK 45.3M |
| Trade & other receivables | NOK 6.5M | NOK 3.6M |
| Cash & equivalents | NOK 123.4M | NOK 41.8M |
| Total equity | NOK 337.1M | NOK 271.9M |
| Non-current liabilities | NOK 54.3M | NOK 54.5M |
| Lease liabilities (non-current) | NOK 300.0K | NOK 0 |
| Current liabilities | NOK 22.9M | NOK 4.4M |
| Lease liabilities (current) | NOK 437.0K | NOK 0 |
| Deferred tax liabilities | NOK 54.0M | NOK 54.5M |
| Derived metrics | ||
| Free cash flow | -NOK 24.1M | -NOK 64.1M |
| Return on equity | -12.5% | -9.8% |
| Cash conversion ratio | 0.57× | 2.41× |
| Capex coverage | -171.27× | — |
| Other reported items | ||
| Additional Paidin Capital | NOK 187.3M | NOK 184.5M |
| Adjustments For Depreciation and Amortisation Expense | NOK 2.4M | NOK 717.0K |
| Adjustments For Increase Decrease In Trade Account Payable | NOK 13.1M | NOK 0 |
| Adjustments For Interest Expense | NOK 98.0K | NOK 0 |
| Adjustments For Interest Income | NOK 1.7M | NOK 2.0M |
| Adjustments For Sharebased Payments | NOK 2.8M | NOK 2.1M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | NOK 0 | -NOK 1.2M |
| Cash and Cash Equivalents In Subsidiary Or Businesses Acquired Or Disposed2013 | NOK 0 | NOK 4.3M |
| Comprehensive Income Attributable To Owners of Parent | -NOK 42.2M | -NOK 29.1M |
| Current Payables On Social Security and Taxes Other Than Income Tax | NOK 1.1M | NOK 0 |
| Current Tax Liabilities Current | NOK 0 | NOK 0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | NOK 0 | NOK 1.2M |
| Equity and Liabilities | NOK 414.4M | NOK 330.8M |
| Expense By Nature | NOK 43.9M | NOK 7.2M |
| Finance Income | NOK 1.7M | NOK 2.0M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | NOK 0 | -NOK 250.0K |
| Income Taxes Paid Refund Classified As Operating Activities | NOK 0 | NOK 759.0K |
| Increase Decrease In Cash and Cash Equivalents | NOK 81.6M | -NOK 56.9M |
| Increase Decrease Through Sharebased Payment Transactions | NOK 2.8M | NOK 2.1M |
| Interest Paid Classified As Financing Activities | NOK 98.0K | NOK 0 |
| Interest Received Classified As Investing Activities | NOK 1.7M | NOK 2.0M |
| Issued Capital | NOK 56.1M | NOK 46.7M |
| Liabilities | NOK 77.2M | NOK 58.9M |
| Other Comprehensive Income | — | -NOK 2.5M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | NOK 0 | -NOK 932.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | NOK 0 | -NOK 1.6M |
| Other Current Liabilities | NOK 6.1M | NOK 2.3M |
| Other Expense By Nature | NOK 26.6M | NOK 3.5M |
| Payments For Share Issue Costs | NOK 9.7M | NOK 319.0K |
| Proceeds From Issuing Shares | NOK 114.3M | NOK 147.0K |
| Profit Loss From Continuing Operations | -NOK 42.2M | -NOK 5.6M |
| Profit Loss From Discontinued Operations | NOK 0 | -NOK 21.0M |
| Retained Earnings | -NOK 63.1M | -NOK 20.9M |
| Share Issue Related Cost | NOK 9.7M | NOK 319.0K |
| Share Premium | NOK 156.8M | NOK 61.5M |
| Trade and Other Current Payables To Trade Suppliers | NOK 15.2M | NOK 2.1M |
Every line item above is a fact tagged in THOR MEDICAL ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.